Compare iShares MBS ETF (MBB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Zoetis Inc — how do they compare? iShares MBS ETF trades at $89.79 (market cap $35.41B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares MBS ETF is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Zoetis Inc for 70 Days on average.
| MBB | ZTS | |
|---|---|---|
Market Cap | $35.41B | $30.20B |
Volume | 5,388,525 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $147.53 |
52-Week Low | $89.09 | $69.09 |
Typical Hold Time | 96 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.73 with a slight 0.57% daily gain, though technical indicators signal bearish momentum with moving averages and ADX both in sell territory. The ETF recently hit a 52-week low of $91.02 in September 2026, reflecting pressure from rising intermediate-term rates and inflation concerns. Recent institutional activity shows mixed sentiment, with Corient Private Wealth increasing its position by 28.3% while short interest surged 98.3% to 6.57 million shares as of September 15, 2026.
The outlook remains cautious due to interest rate sensitivity and convexity risk in mortgage-backed securities. While Norway's $2.3 trillion sovereign wealth fund rotation into MBS provides institutional support, the intermediate duration of 5.68 years exposes MBB to Fed policy uncertainty. Key risks include persistent inflation and borrower prepayment behavior limiting upside potential.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
